Company overview
Metrion Biosciences is a specialized contract research organization (CRO) offering ion channel screening services for drug discovery and safety pharmacology. The company provides high-throughput screening (HTS), automated and manual patch clamp electrophysiology, fluorescence-based assays, and custom cell line generation across cardiac, neuroscience, and pain research targets. With over 250 years of collective ion channel expertise, Metrion delivers customized assays from hit identification through lead optimization and mechanism-of-action studies.
Metrionbiosciences is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services partner serving United States & Americas. Core focus areas include ion channel screening, patch clamp electrophysiology, high-throughput screening hts, cardiac safety pharmacology, drug discovery cro.
Industry categories: CRO & Clinical Services. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Metrionbiosciences include Cro — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://metrionbiosciences.com/
- Categories
- CRO & Clinical Services
- Markets served
- United States & Americas
- Keywords
- ion channel screening, patch clamp electrophysiology, high-throughput screening hts, cardiac safety pharmacology, drug discovery cro
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What ion channel screening platforms does Metrion offer?
- Metrion employs multiple screening platforms including automated patch clamp systems (QPatch 48, QPatch 384, Patchliner), manual patch clamp electrophysiology, fluorescence-based assays (FLIPR Penta, Qube-384), plate-based impedance, and label-free detection methods. These platforms support screening campaigns from hit finding through detailed biophysical characterization and mechanism-of-action studies.
- Does Metrion provide cardiac safety screening?
- Yes, Metrion offers comprehensive cardiac ion channel screening services including GLP-hERG testing and Comprehensive In Vitro Proarrhythmia Assay (CiPA) compliant human cardiac ion channel screening assays. These services support regulatory requirements for cardiac safety profiling of drug candidates.
- Can Metrion generate custom cell lines for specific ion channel targets?
- Yes, Metrion has in-house capabilities to generate and validate novel ion channel cell lines, including complex multi-subunit channels. The company's team has over 30 years of experience in molecular biology and stable cell line generation, enabling development of robust assays that deliver consistent, reproducible, and biologically relevant data.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
